Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases

Abstract

Background: Our aim is to report treatment efficacy and toxicity of patients treated by robotic (Cyberknife®) stereotactic body radiotherapy (SBRT) for oligorecurrent lung metastases (ORLM). Additionally we wanted to evaluate influence of tumor, patient and treatment related parameters on local control (LC), lung and distant progression free-(lung PFS/Di-PFS) and overall survival (OS). Methods: Consecutive patients with up to 5 ORLM (confirmed by FDG PET/CT) were included in this study. Intended dose was 60Gy in 3 fractions (prescribed to the 80% isodose volume). Patients were followed at regular intervals and tumor control and toxicity was prospectively scored. Tumor, patient and treatment data were analysed using competing risk-and Cox regression. Results: Between May 2010 and March 2016, 104 patients with 132 lesions were irradiated from primary lung carcinoma (47%), gastro-intestinal (34%) and mixed primary histologies (19%). The mean tumor volume was 7.9 cc. After a median follow up of 22 months, the 1, 2 and 3 year LC rate (per lesion) was 89.3, 80.0 and 77.8% respectively. The corresponding (per patient) 1, 2 and 3 years lung PFS were 66.3, 50.0, 42.6%, Di-PFS were 80.5, 64.4, 60.6% and OS rates were 92.2, 80.9 and 72.0% respectively. On univariable analysis, gastro-intestinal (GI) as primary tumor site showed a significant superior local control versus the other primary tumor sites. For OS, significant variables were primary histology and primary tumor site with a superior OS for patients with metastases of primary GI origin. LC was significantly affected by the tumor volume, physical and biologically effective dose coverage. Significant variables in multivariable analysis were BED prescription dose for LC and GI as primary site for OS. The vast majority of patients developed no toxicity or grade 1 acute and late toxicity. Acute and late grade 3 radiation pneumonitis (RP) was observed in 1 and 2 patients respectively. One patient with a centrally located lesion developed grade 4 RP and died due to possible RT-induced pulmonary hemorrhage. Conclusions: SBRT is a highly effective local therapy for oligorecurrent lung metastases and could achieve long term survival in patients with favourable prognostic features.

Stereotactic Body Radiotherapy for Patients with Lung Oligometastatic Disease: A Five-Year Systematic Review

“…The ECOG index ranged from 0 to 3, with only one study reporting ECOG for three patients [ 16 ]. Oligometastatic disease was defined as one to five metastases in eight articles [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ], one to four metastases in one article [ 25 ], one to three metastases in three articles [ 26 , 27 , 28 ], and six articles did not specify any definition [ 16 , 29 , 30 , 31 , 32 , 33 ].…”

“…Surgery was used at least once before SBRT in 164 patients, but no thermoablation before SBRT was identified. Only two authors specified surgery for metastases, which represented 44 patients [ 18 , 21 , 22 , 24 , 25 , 27 , 30 , 33 ]. The 2-year LC, PFS, and OS ranged from 31% to 93%, from 10% to 38%, and from 40% to 85%, respectively.…”

“…the only LC prognostic factor in Berkovic et al [24]. Figure 2 shows local control rates as a function of 10GyBED (Figure 2).…”

Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy

“…Visceral metastases (VM) are the most common metastases from CRC that are treated with SBRT [16] and much of the literature to date has focussed on either liver or lung metastases [17] . In the SABR-COMET trial [7] most patients had visceral metastases, while only 3 (6%) of metastases treated with SBRT were in lymph nodes.…”

Repeat Thoracic Stereotactic Body Radiation Therapy (SBRT) for Nonsmall Cell Lung Cancer: Long-Term Outcomes, Toxicity, and Dosimetric Considerations

“…However, there remains considerable rates of acute and late toxicities of the lung, chest wall, esophagus, and bronchial tree, with at least 8 series reporting fatal grade 5 toxicities. [12][13][14][15][16][17][18][19] Correspondingly, there is a scarcity of data in regard to dose-volume constraints or guidelines for safe reirradiation in this setting.…”